Literature DB >> 2079368

[Treatment results using cefixime for bacterial respiratory tract infections].

L Leonhardt1.   

Abstract

In a prospective open clinical trial 20 patients with the diagnosis bacterial respiratory tract infection and underlying chronic obstructive lung disease were treated for 13 to 17 days with 200 mg cefixime b. i. d. 14 of 16 evaluable patients were treated successfully. In one patient the clinical symptoms remained unchanged and in another patient cefixime treatment failed. Ten of the 16 evaluable patients showed a positive baseline culture. In nine of these patients the initially isolated pathogens could be eliminated. In one patient, in whom cefixime therapy failed, change of pathogens was noticed after the end of treatment. Four of the 20 patients treated with cefixime reported side effects (gastritis, three; fungal dermatitis, one). In the patient with fungal dermatitis cefixime therapy was stopped.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2079368     DOI: 10.1007/BF01644627

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.

Authors:  C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods.

Authors:  G V Doern; T A Tubert
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 3.  Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections.

Authors:  R Kiani; D Johnson; B Nelson
Journal:  Am J Med       Date:  1988-09-16       Impact factor: 4.965

4.  Safety and efficacy of cefixime versus cefaclor in respiratory tract infections.

Authors:  P Dorow
Journal:  J Chemother       Date:  1989-08       Impact factor: 1.714

5.  Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.

Authors:  J W Stone; G Linong; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-02       Impact factor: 5.790

6.  Cefixime versus amoxicillin/clavulanic acid in lower respiratory tract infections.

Authors:  H M Beumer
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.